On December 15, 2021 Curium reported that welcomes Sakir Mutevelic MD, MSc. As Chief Medical Officer, Sakir leads Curium’s global medical strategy and clinical development for diagnostic and therapeutic radiopharmaceuticals (Press release, Curium, DEC 15, 2021, View Source [SID1234606798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this role, he develops and leads Curium`s product pipeline growth initiatives, to drive product evolution and portfolio expansion across radiopharmaceutical diagnostics, companion diagnostics and therapeutics — ensuring the Curium Group fulfils its "Life Forward" mission to transform and improve disease management and patient lives. This includes managing and coordinating strategic partnerships, clinical development planning and operational execution, managing the clinical aspects of regulatory strategies and interactions with health authorities, and supporting Curium`s strategic initiatives from medical and clinical development perspective. Sakir is a member of Curium’s Global Leadership Team.

Sakir holds a medical doctor degree and master’s degree in pharmacology and has more than 25 years of professional experience in the pharmaceutical industry, with profound clinical experience and successful clinical development of both new chemical and biological entities in oncology and hematology, from early to late-stage clinical development as well as global regulatory submissions and approvals. Prior to his time at Curium, he served in different strategic and operational functions, with increasing responsibility at country, regional and global levels at Boehringer Ingelheim, Baxter, Baxalta, Shire, Servier and AAA/Novartis.